MBXClinical Trials•globenewswire•September 4, 2025 at 12:00 PM

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

Sentiment:Neutral (60)

Summary

(NASDAQ:MBX) Preclinical data support the potential for improved weight loss and tolerability with once-monthly administration of MBX 4291 Preclinical data support the potential for improved weight loss and tolerability with once-monthly administration of MBX 4291

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on September 4, 2025 by globenewswire